AzTrials
AzTrials

Premature LabourEcho-colNCT02598323

Prevention and Treatment of Premature Labour for Asymptomatic Pregnant Women

A study testing ultrasound in people with Premature Labour, run by Assistance Publique Hopitaux De Marseille at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

State of the question and research objective: International trials have shown that ultrasound measurement of the cervix identifies a population at high risk of preterm delivery. In case of short neck several types of treatments can be recommended: progesterone, the establishment of a strapping or pessary. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Premature Labour
What is being tested?
ultrasound
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
3,500 participants
Where
1 siteFrance
Study dates
Nov 2015to Nov 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age> 18 years,
  • pregnancy with single fetus,
  • gestational age between 16SA and 26SA,
  • asymptomatic patients, that is to say, without sign of preterm labor layout

Who cannot join

  • Maternal Pathology (Pre Eclampsia, non-insulin dependent diabetes, insulin dependent gestational diabetes or unbalanced)
  • uterine malformation
  • fetal malformation or fetal chromosomal abnormality
  • premature Work in Progress (cervix dilated to more than 2 cm or regular uterine contractions and felt)
  • Signs of chorioamnionitis
  • Allergy to progesterone
  • Taking progesterone in the month preceding the inclusion

Trial locations and contacts

1 site in 1 country.

Cecile CHAU, MD contact

cecile.chau@ap-hm.fr

France1 site
  • AP-HM

    Marseille

    Cecile Chau, MD, cecile.chau@ap-hm.fr

Other trials in France

About this study

Official title: Premature Labour Screening by Cervical Ultrasound for Asymptomatic Pregnant Women in the PACA Region. Various Treatment Strategies : 1. Progesterone 200mg (Vaginal Way) 2. Pessary 3. Vaginal Stitching 4. Rest

State of the question and research objective: International trials have shown that ultrasound measurement of the cervix identifies a population at high risk of preterm delivery. In case of short neck several types of treatments can be recommended: progesterone, the establishment of a strapping or pessary. These three treatments reduce the risk of preterm delivery. There is no French study.

The objective of this study is to reduce prematurity in the PACA region Monaco-Corsica by introducing a routine ultrasound screening strategy asymptomatic short necks.

Read more

Population concerned: All patients with active singleton pregnancy between 16 and 26 SA SA are eligible to ultrasound of the cervix.

  • Primary endpoint: delivery rate before 37 weeks.
  • Criteria secondary judgments rate of deliveries before 37 weeks, neonatal mortality morbidity.

Expected result: a prematurity of 50%

Read the detailed description

State of the question and research objective: International trials have shown that ultrasound measurement of the cervix identifies a population at high risk of preterm delivery. In case of short neck several types of treatments can be recommended: progesterone, the establishment of a strapping or pessary. These three treatments reduce the risk of preterm delivery. There is no French study.

The objective of this study is to reduce prematurity in the PACA region Monaco-Corsica by introducing a routine ultrasound screening strategy asymptomatic short necks.

Expected result: a prematurity of 50%

Population concerned: All patients with active singleton pregnancy between 16 and 26 SA SA are eligible to ultrasound of the cervix.

Method of observation and deduction investigation: Study before / after comparing two periods: period A (2013) and Period B (2015).

  • Primary endpoint: delivery rate before 37 weeks.
  • Criteria secondary judgments rate of deliveries before 37 weeks, neonatal mortality morbidity.

Data flow mode:

Duration and terms of organization of research: The actual duration of the study (preparation and implementation, monitoring and inclusions) is set at 36 months. This study will be conducted in the context of networks. All maternity hospitals belonging to these networks will be invited to participate. Referents investigating doctors will be appointed.

The attaché of clinical research in collaboration with the Network Coordinator, Michele Marcot, get back the data for the year 2013 by the transfer records examination, delivery specifications, reviews of the hospitalization mother and child.

Data collection for 2015 will be based on a collection form that will complement the investigators involved in the project at the inclusion of the patient.

These sheets will be collected in real time by the RCAF in charge of monitoring the study will proceed to their seizure.

Positive cases (short necks - less than 25mm) will be offered or not progesterone treatment, banding or the establishment of a pessary according to the habits of the practitioner and the service protocol.

If treatment with progesterone is retained, it is Vaginal Progesterone 200mg, natural micronized progesterone without excipients with known effect in capsule form.

Data Analysis Method: Statistical analysis will be initiated only after verification of the validity of the database (queries broadcast from clinicians involved in the study, consistency checks). There is a procedure and data anonymization algorithm giving each individual a number. A lookup table is available, separate from the operating base. Only the number will be entered into the computer database. The database will then be frozen. After the base gel, the consolidated data will be processed by the statistician. Data analysis will be performed using the SPSS Version 17.0 software for Windows by the statistician of the Unit for Clinical Research Methodology (Loundou Anderson, head Prof. Pascal Auquier).

Statistical significance tests will be set at 5%. The type of unilateral or bilateral test will depend on the chosen alternative, especially based on the results already available in previous studies.

The qualitative variables are expressed in terms of numbers and percentages, and quantitative variables will be reported using the usual parameters of position (mean, median) and dispersion (standard deviation, range). The normality of the distributions of quantitative data will be systematically searched using the Shapiro-Wilks test. If variables are not normally distributed, conventional processing techniques (logarithmic, ...) will be implemented.

Initially, a comparability study populations for inclusion will be made on all the variables collected at that time: socio-demographic and clinical (using Mantel-Haenszel test, the Chi-2 or accurate Fisher for qualitative variables, and Student's t test or ANOVA for quantitative variables) to reveal potential confounding factors to consider when analyzing the criteria of judgment. Comparisons between the study populations will also be conducted on all the criteria of secondary judgments. Adjustments will be made on the variables identified as confounding factors by conducting multivariate analysis (analysis of variance, multivariate logistic regression).

Justification of the number of subjects or power analysis: The prematurity rate was 7.4% in 2013 in France (PACA, Périnat data 2010).

We expect a reduction in this rate of 1.5 points (or 6%) over the period 2015 referring to the reduction of prematurity obtained by Kiss, et al, 2003.

To achieve this reduction in preterm birth rate, include 3500 patients in each period. Considering the selection criteria and the active files of the various partners, the inclusion of patients in the period 3500 2014 is quite achievable.

(44,000 births per year at the network level, among which are ensuring that 10% of them meet the predefined criteria). Regarding the second period, the reasoning is the same; among the list of eligible patients, a random draw will be conducted to determine the 3500 patients representing this period. Thus for 3500 patients included in the period 2014, 10% will have a short neck or 350 patients who will be offered the Progesterone, a banding or the establishment of a pessary.

Being tested
ultrasound
Medical subject headings
Obstetric Labor, Premature

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ultrasoundDevice

Study groups in NCT02598323
Study groupRoleWhat they receive
patients with active singleton pregnancy between 16 and 26 SAExperimentalNot described
Receives: Device: ultrasound

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. delivery rate before 37 weeks

    Measured: 21 weeks maximum

Secondary outcomes (3)
  1. neonatal mortality

    Measured: about 30 weeks

  2. rate of newborns admitted to intensive care in the first month of life

    Measured: about 30 weeks

  3. length of stay in intensive care

    Measured: about 30 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Nov 2015 (estimated)
  2. Study startNov 2015
  3. Primary completionNov 2017 (estimated)
  4. Study completionNov 2018 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
3,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02598323
Sponsor's protocol ID
2014-24
Other IDs
AP-HM
Acronym
Echo-col
Status last verified
Nov 2015
First submitted
4 Nov 2015
Last updated
5 Nov 2015
Results posted
No
Data monitoring committee
No

Publications

  • Figarella A, Chau C, Loundou A, d'Ercole C, Bretelle F. The introduction of a universal transvaginal cervical length screening program is associated with a reduced preterm birth rate. Am J Obstet Gynecol. 2023 Feb;228(2):219.e1-219.e14. doi: 10.1016/j.ajog.2022.07.046. Epub 2022 Aug 4.

    PubMed 35932876

Questions about this trial

What is this clinical trial studying?

A study testing ultrasound in people with Premature Labour, run by Assistance Publique Hopitaux De Marseille at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Cecile CHAU, MD (cecile.chau@ap-hm.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

delivery rate before 37 weeks (time frame: 21 weeks maximum). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02598323, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in